NCT02393248 2023-01-06Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Incyte CorporationPhase 1/2 Terminated201 enrolled 71 charts
NCT02012231 2020-10-19Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.Fore BiotherapeuticsPhase 1 Terminated5 enrolled